Abivax SA research snapshot
ABVX AI stock analysis currently reads Abivax SA as a late-stage biotechnology company whose value depends primarily on obefazimod, an oral miR-124 enhancer being developed for ulcerative colitis and Crohn's disease. The Phase 3 ABTECT results were positive, the company closed a $920 million public offering on July 6, 2026, and it reported constructive FDA pre-NDA feedback on July 30 with an NDA submission still on track for the end of 2026. At the August 3, 2026 data cutoff, ABVX closed at $124.92 on July 31, and 11 analysts rate the stock Strong Buy with an average target of $165.91. This ABVX AI stock analysis uses conditional scenarios and source-backed facts for information only. It is not investment advice.
Current price
$124.92 at the July 31, 2026 Nasdaq close
Market cap
$9.90 billion calculated from 79.29 million shares; StockAnalysis reports about $10.54 billion, which appears to use an earlier price snapshot
AI score
70 / 100
Rating
Late-stage biotech with positive ABTECT data, FDA pre-NDA alignment, a large cash balance, and still binary approval plus launch risk
Trend status
Longer-term uptrend intact above the 50-day and 200-day averages; short-term pullback after the July peak and financing repricing
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Abivax is a focused clinical-stage biotech built around obefazimod, a once-daily oral candidate for chronic inflammatory bowel disease. It has clinical proof and regulatory alignment but no approved product revenue. | High |
| Moat | The potential moat is the differentiated miR-124 mechanism, accumulated clinical data, patent estate, and regulatory know-how. Network effects, switching costs, and commercial scale are not yet proven. | Medium |
| Management | CEO Marc de Garidel has more than 40 years of pharma and biotechnology experience. The July commercial leadership appointments and the new cash balance support launch preparation, but post-approval execution at Abivax remains untested. | Medium |
| Financial trend | FY2025 revenue fell to EUR 4.57 million while the operating loss widened to EUR 246.1 million and operating cash use reached EUR 161.1 million. The July offering improves liquidity but also increases the share count. | High |
| Valuation | At about $10 billion of equity value, ABVX has no meaningful PE or FCF valuation because earnings and free cash flow are negative. The market price reflects substantial expected value from approval and future sales. | High |
| Technical trend | The July 31 close at $124.92 sits below the calculated 20-session SMA of $133.00 and above the 50-day SMA of $118.54, inside a wide post-offering trading range rather than a fresh breakout. | Medium |
| Risk level | Risk is high because one lead asset drives most of the thesis, regulatory and safety outcomes remain ahead, commercial competition is strong, and the recent offering creates dilution and repricing risk. | High |
| AI confidence | Confidence is higher for historical facts and lower for any forecast that assumes approval, pricing, market share, or a specific launch timeline. | Medium-high data confidence |
| Investment certainty | The clinical thesis is credible but not yet a durable business thesis. Investment certainty depends on the FDA path, commercial positioning, and evidence that the balance sheet can fund launch without repeated dilution. | Low-medium |
ABVX AI stock forecast
The ABVX AI stock forecast is a conditional framework, not a price promise. A three-scenario EPS valuation is not decision-useful because FY2025 EPS was negative, so the ranges below are market-repricing bands tied to approval, commercialization, cash use, and clinical execution rather than fabricated intrinsic-value targets.
$170 to $220
More likely if the Q4 2026 NDA is submitted on schedule, FDA review stays supportive, obefazimod reaches approval, the U.S. launch earns strong prescriber and payer adoption, and Crohn's disease data adds a second growth option.
$120 to $165
More likely if the regulatory path advances but approval timing, pricing, launch spending, or market share remain uncertain. The new cash can fund the program, while the stock continues to trade on milestones and analyst targets rather than current earnings.
$70 to $115
More likely if the FDA requests additional work, safety or manufacturing issues appear, approval is delayed or denied, commercial uptake disappoints, Crohn's disease data weakens the platform story, or further financing becomes necessary.
ABVX AI technical analysis
ABVX AI technical analysis shows a longer-term uptrend with a short-term pullback as of the July 31, 2026 close. Price is below the calculated 20-session SMA of $133.00 and above the 50-day SMA of $118.54, with RSI near neutral at 49.20. The stock spent July consolidating after the June rally and the July financing, and volume remains elevated around catalyst dates.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $124.92 | StockAnalysis historical data, July 31, 2026 Nasdaq close. The close was below the $127.51 intraday high and above the $120.62 low. |
| Immediate support | $118.18 to $120.62 | The July 29 session low and the July 31 session low. A close below this zone would weaken the near-term consolidation structure. |
| Financing reference | $125.00 | The July 2026 public offering price per ADS. Price is trading just below it, so it is a watched reference for post-offering acceptance rather than a guaranteed technical floor. |
| First resistance | $130.00 to $134.74 | Recent July highs from July 27 and July 21. A close above this zone with confirming volume would improve short-term momentum. |
| Higher resistance | $138.32 to $148.83 | The July 20 high, the July 6 close, and the 52-week high area. A decisive break would put the stock back into price discovery. |
| Moving averages | 20-session SMA $133.00 (calculated); 50-day SMA $118.54; 200-day SMA $116.83 | The 20-session average is calculated from the last 20 completed daily closes available in the source snapshot through July 31, 2026. The 50-day and 200-day values come from the StockAnalysis statistics page. |
| Momentum | -13.24% from the July 6 close to July 31; +29.38% from the June 12 close; +86.20% from the 52-week low | The mixed time-frame result shows strong medium-term momentum with a recent pullback. RSI is 49.20, roughly neutral after the earlier extremes. |
| Volume | 1,235,261 shares on July 31; 4.02 million on July 2; 8.95 million on June 30; 16.1 million on June 2 | Volume expanded sharply around the financing and clinical milestones and has since normalized toward the 20-day average of about 1.07 million. |
| Volatility | 52-week range $67.09 to $148.83 | The broad range reflects the binary nature of clinical-stage biotech valuation and makes event gap risk more important than any single indicator. |
| Invalidation | Close below $118, then deeper risk below $116.83 | A close below the 50-day SMA and recent lows would weaken the near-term structure. A break below the 200-day SMA would weaken the medium-term trend setup. |
ABVX AI trading strategy
The ABVX AI trading strategy is a non-personal framework for a milestone-driven biotechnology stock. Any use should include live quotes, position sizing, clinical and regulatory calendars, SEC filings, and explicit rules for event gaps. It is not investment advice.
Wait for a close above the $130.00 to $134.74 resistance zone, then look for a retest that holds with volume and no adverse regulatory or safety news. A later break above $148.83 would confirm a new high, but it would not remove approval risk.
Treat a close below $120.62 as a failed near-term attempt and a close below $118 as a deeper invalidation of the current trend framework.
A pullback toward $118 to $125 can be monitored only after price stabilizes and the clinical thesis remains unchanged. Compare any bounce with volume, the offering price, new company filings, and the next regulatory milestone.
Do not treat a sharp decline as automatically oversold. A regulatory, safety, or manufacturing development can move through support without a technical bounce.
Track the Q4 2026 NDA submission, FDA acceptance and review milestones, ABTECT safety follow-up, ENHANCE-CD data expected in mid-2027, cash use, launch hiring and commercial appointments, payer access, and any partnership or commercialization update.
Reduce confidence if the NDA slips, the FDA requests material additional work, safety interpretation changes, cash burn accelerates, or management issues new shares before reaching a commercial funding milestone.
Investment research summary
Abivax is trying to turn one differentiated oral anti-inflammatory mechanism into a commercial medicine. Obefazimod is designed to increase miR-124, a natural regulator of inflammatory pathways, and is being tested in ulcerative colitis and Crohn's disease. The company has clinical assets and launch preparation, not a recurring product business yet.
The current moat is prospective rather than commercial: a novel mechanism, an expanding clinical dataset, intellectual property, trial execution, and regulatory experience. There are no meaningful network effects or switching costs today, and competing IBD therapies can limit pricing and adoption even after approval.
The thesis can fail through a regulatory request, an unexpected safety signal, manufacturing delay, a weaker benefit-risk assessment, poor payer access, slow physician adoption, or an unsuccessful Crohn's program. The July offering reduces near-term liquidity risk but raises the share count and creates a higher valuation hurdle.
CEO Marc de Garidel has more than 40 years in pharma and biotechnology and previously led transactions involving Corvidia Therapeutics and CinCor Pharma. The July 2026 offering at $125 per ADS, with estimated net proceeds of $874.1 million, and the four commercial leadership appointments in July show preparation for a potential U.S. launch. The record of post-approval execution remains untested at Abivax.
Inflammatory bowel disease has durable medical need and a large treatment market, while oral therapies can be attractive compared with injectable biologics. The market is also crowded, with established biologics, small molecules, payer negotiations, and changing treatment guidelines. A positive clinical result does not guarantee a durable commercial advantage.
At a calculated equity value of about $9.9 billion, ABVX traded at a very large multiple of FY2025 revenue because revenue was only EUR 4.57 million and FY2025 EPS was negative. PE and FCF yield are not useful as positive valuation anchors. The margin of safety depends on approval probability, future sales, cash runway, and the price paid for those uncertain outcomes.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ABVX latest completed-session price | $124.92 at the July 31, 2026 Nasdaq close | StockAnalysis historical data | August 3, 2026 |
| Market capitalization | $9.90 billion calculated as $124.92 x 79.29 million shares; reported market cap about $10.54 billion; verification variance 6.03%, with the reported figure appearing to use an earlier price snapshot | StockAnalysis and financial_rigor.py | August 3, 2026 |
| Shares outstanding reference | 79.29 million shares outstanding per StockAnalysis, up 16.25% year over year; 7.36 million ADSs were issued in the July 2026 offering | StockAnalysis statistics and July 2026 offering release | August 3, 2026 |
| Five-year revenue trend | EUR 11.96M in 2021, EUR 4.58M in 2022, EUR 4.62M in 2023, EUR 12.45M in 2024, and EUR 4.57M in 2025 | StockAnalysis financials | August 3, 2026 |
| FY2025 operating loss and net loss | Operating loss EUR 246.06M; net loss EUR 336.1M; basic EPS -EUR 4.83 | StockAnalysis financials and Abivax 2025 Form 20-F | August 3, 2026 |
| Operating cash use and free cash flow | Cash used in operating activities was EUR 161.13M in 2025; StockAnalysis reports FY2025 free cash flow of -EUR 161.27M | StockAnalysis cash flow statement | August 3, 2026 |
| Cash and short-term investments | EUR 516.69M at December 31, 2025; EUR 477.42M at March 31, 2026 before the July offering. After the offering, Abivax said current resources are expected to fund operations into Q4 2029. | StockAnalysis balance sheet and July 2026 offering release | August 3, 2026 |
| ABTECT Phase 3 maintenance result | At Week 44, clinical remission was 50.8% for 25 mg and 51.3% for 50 mg versus 10.4% for placebo; both primary comparisons had p<0.0001 in N=580 | Abivax ABTECT maintenance release | August 3, 2026 |
| ABTECT Maintenance Part 2 result | 37.2% of induction non-responders achieved clinical remission and 34.5% achieved endoscopic remission at Week 44 after continued 50 mg treatment | Abivax ABTECT Maintenance Part 2 release | August 3, 2026 |
| FDA pre-NDA interaction | On July 30, 2026, Abivax announced successful completion of a positive pre-NDA interaction with the FDA, with alignment on the planned NDA submission strategy, content, and format. The company remains on track to submit its first NDA for obefazimod by the end of 2026. | Abivax July 30, 2026 press release | August 3, 2026 |
| Regulatory and clinical milestones | Planned U.S. NDA submission for obefazimod by the end of 2026; Crohn's disease Phase 2b induction topline results expected mid-2027 | Abivax investor relations and clinical program releases | August 3, 2026 |
| July 2026 public offering | 7.36 million ADSs at $125 each; gross proceeds about $920.0M and estimated net proceeds about $874.1M (about EUR 767.1M); funds operations into Q4 2029 | Abivax offering closing release | August 3, 2026 |
| Commercial leadership appointments | On July 23, 2026, Abivax announced four commercial leadership appointments covering marketing, patient services, sales and commercial operations, and market access, ahead of a potential U.S. launch | Abivax July 23, 2026 press release | August 3, 2026 |
| Analyst consensus and targets | 11 analysts rate ABVX Strong Buy with an average 12-month target of $165.91, a low of $142, a median of $170, and a high of $187 | StockAnalysis forecast page | August 3, 2026 |
| Short interest and technical snapshot | Short interest 4.02 million shares (4.67% of shares outstanding); 50-day SMA $118.54; 200-day SMA $116.83; RSI 49.20; 52-week range $67.09 to $148.83 | StockAnalysis statistics and historical data | August 3, 2026 |
| Management reference | Marc de Garidel is CEO; Abivax reports more than 40 years of pharma and biotechnology experience and prior leadership of Corvidia and CinCor transactions | Abivax management profile | August 3, 2026 |
This ABVX AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are conditional scenarios based on available data as of August 3, 2026 and can be wrong if clinical results, regulation, competition, financing, launch execution, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
